BOXED O
WARNING O
: O
WARNING O
: O
( O
A O
) O
BLEEDING O
RISK O
, O
( O
B O
) O
ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
WARNING O
: O
( O
A O
) O
BLEEDING O
RISK O
, O
( O
B O
) O
ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
A O
. O

BLEEDING O
RISK O
* O
BRILINTA O
, O
like O
other O
antiplatelet O
agents O
, O
can O
cause O
significant O
, O
sometimes O
fatal B-NonOSE_AE
bleeding B-OSE_Labeled_AE
( O
5.1 O
, O
6.1 O
) O
. O

* O
Do O
not O
use O
BRILINTA O
in O
patients O
with O
active O
pathological O
bleeding B-Not_AE_Candidate
or O
a O
history O
of O
intracranial B-Not_AE_Candidate
hemorrhage I-Not_AE_Candidate
( O
4.1 O
, O
4.2 O
) O
. O

* O
Do O
not O
start O
BRILINTA O
in O
patients O
undergoing O
urgent O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
( O
5.1 O
, O
6.1 O
) O
. O

* O
If O
possible O
, O
manage O
bleeding B-NonOSE_AE
without O
discontinuing O
BRILINTA O
. O

Stopping O
BRILINTA O
increases O
the O
risk O
of O
subsequent O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
( O
5.4 O
) O
. O

B O
. O
ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
* O
Maintenance O
doses O
of O
aspirin O
above O
100 O
mg O
reduce O
the O
effectiveness O
of O
BRILINTA O
and O
should O
be O
avoided O
( O
2.1 O
, O
5.2 O
, O
14.1 O
) O
. O

EXCERPT O
: O
WARNING O
: O
( O
A O
) O
BLEEDING O
RISK O
, O
and O
( O
B O
) O
ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

BLEEDING O
RISK O
* O
BRILINTA O
, O
like O
other O
antiplatelet O
agents O
, O
can O
cause O
significant O
, O
sometimes O
fatal O
bleeding O
( O
5.1 O
, O
6.1 O
) O
. O

* O
Do O
not O
use O
BRILINTA O
in O
patients O
with O
active O
pathological O
bleeding O
or O
a O
history O
of O
intracranial O
hemorrhage O
( O
4.1 O
, O
4.2 O
) O
. O

* O
Do O
not O
start O
BRILINTA O
in O
patients O
undergoing O
urgent O
coronary O
artery O
bypass O
graft O
surgery O
( O
CABG O
) O
( O
5.1 O
, O
6.1 O
) O
. O

* O
If O
possible O
, O
manage O
bleeding O
without O
discontinuing O
BRILINTA O
. O

Stopping O
BRILINTA O
increases O
the O
risk O
of O
subsequent O
cardiovascular O
events O
( O
5.4 O
) O
. O

ASPIRIN O
DOSE O
AND O
BRILINTA O
EFFECTIVENESS O
* O
Maintenance O
doses O
of O
aspirin O
above O
100 O
mg O
reduce O
the O
effectiveness O
of O
BRILINTA O
and O
should O
be O
avoided O
. O

( O
2.1 O
, O
5.2 O
, O
14.1 O
) O
. O

